Einloggen
E-Mail
Passwort
Passwort anzeigen
Merken
Passwort vergessen?
Watchlisten für Ihre Werte
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON

ALBIREO PHARMA, INC.

(ALBO)
  Bericht
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über ALBIREO PHARMA, INC.
06.01.Albireo Increases 2021 Bylvay (odevixibat) Sales Guidance
05.01.ALBIREO PHARMA : Increases 2021 BylvayTM (odevixibat) Sales Guidance - Form 8-K/A
05.01.ALBIREO PHARMA, INC. Results of Operations and Financial Condition, Change in Director..
05.01.Albireo Increases 2021 Bylvay™ (odevixibat) Sales Guidance
05.01.ALBIREO PHARMA, INC. : Results of Operations and Financial Condition, Change in Directors ..
05.01.ALBIREO PHARMA : Increases 2021 BylvayTM (odevixibat) Sales Guidance - Form 8-K
05.01.Albireo Pharma, Inc. Announces Resignation of Roger A. Jeffs as Independent Director
03.01.Immix Biopharma Shares More Than Double on FDA Designation
2021Albireo Pharma's Early Stage Trial Confirms Safety, Tolerability of Liver Disease Drug
2021Albireo Announces Positive Topline Data from Phase 1 Study of A3907
2021Albireo Announces Positive Topline Data from Phase 1 Study of A3907
2021Albireo Presenting New Bylvay™ (odevixibat) Data at NASPGHAN 2021
2021Albireo Pharma, Inc. Presenting New Bylvay™ Data at NASPGHAN 2021
2021ALBIREO PHARMA : Announces Changes to R&D Organization - Form 8-K
2021ALBIREO PHARMA, INC. : Entry into a Material Definitive Agreement, Change in Directors or ..
2021Albireo Announces Changes to R&D Organization
2021Albireo Pharma, Inc. Announces Executive Changes
2021Albireo Expands Leadership with Constantine Chinoporos as Chief Business Officer
2021Albireo Pharma, Inc. Announces Constantine Chinoporos as Chief Business Officer
2021ALBIREO PHARMA : Post-AASLD Business Update
2021Albireo Announces New Phase 3 Data for Bylvay™ (odevixibat) in PFIC and First Rev..
2021Albireo Announces New Phase 3 Data for Bylvay? in Pfic and First Reveal of New Next Gen..
2021Albireo to Present at Upcoming Investor Conferences
2021Albireo Pharma Swings to Q3 Gain on Sale of Priority Review Voucher; Shares Fall
2021ALBIREO PHARMA, INC. Management's Discussion and Analysis of Financial Condition and R..
2021Albireo Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months End..
2021Albireo Reports Q3 Financial Results and Business Update - Form 8-K
2021Earnings Flash (ALBO) ALBIREO PHARMA Posts Q3 Revenue $3.7M
2021Albireo Reports Q3 Financial Results and Business Update
2021Albireo to Report Third Quarter 2021 Financial Results on November 4
2021ALBIREO PHARMA : to Showcase New Data at AASLD The Liver Meeting 2021
2021Albireo to Showcase New Data at AASLD The Liver Meeting® 2021
2021ALBIREO PHARMA : Announces Exclusive Licensing Agreement with Jadeite Medicines for Bylvay..
2021ALBIREO PHARMA : Signs Bylvay Licensing Deal With Jadeite Medicines
2021ALBIREO PHARMA : Announces Exclusive Licensing Agreement with Jadeite Medicines for Bylvay..
2021Albireo Pharma, Inc. Announces Exclusive Licensing Agreement with Jadeite Medicines for..
2021Albireo Recognizes PFIC Awareness Day 2021
2021ALBIREO PHARMA : Recognizes PFIC Awareness Day 2021
2021MIRUM PHARMACEUTICALS : oral drug becomes first U.S. approved Alagille syndrome therapy
2021ALBIREO PHARMA : Announces Bylvay (odevixibat) Now Available in Germany
2021ALBIREO PHARMA : Launches Bylvay in Germany
2021ALBIREO PHARMA : Announces Bylvay® (odevixibat) Now Available in Germany
2021Albireo Pharma, Inc. Announces Bylvay® Now Available in Germany
2021ALBIREO PHARMA : Reports Inducement Grant Under Nasdaq Listing Rule 5635(4)
2021ALBIREO PHARMA : Receives UK MHRA Approval of Bylvay (odevixibat)
2021Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2021ALBIREO PHARMA : Wins UK Ok of Bylvay for Progressive Familial Intrahepatic Cholestasis
2021ALBIREO PHARMA : Receives UK MHRA Approval of Bylvay® (odevixibat)
2021Albireo Pharma, Inc. Receives UK MHRA Approval of Bylvay®
2021ALBIREO PHARMA : To Sell Priority Review Voucher For $105 Million
2021ALBIREO PHARMA : PRV was granted to Albireo with the FDA approval of BylvayTM (odevixibat)..
2021ALBIREO PHARMA, INC. : Entry into a Material Definitive Agreement, Financial Statements an..
2021Albireo Sells Priority Review Voucher (PRV) for $105 Million
2021Albireo to Present at Upcoming Investor Conferences
2021ALBIREO PHARMA : Enters Deal With Genpharm to Commercialize Liver Disease Drug in Saudi Ar..
2021ALBIREO PHARMA : Management's Discussion and Analysis of Financial Condition and Results o..
2021ALBIREO PHARMA : Earnings Flash (ALBO) ALBIREO PHARMA Reports Q2 Revenue $2.4M, vs. Street..
2021ALBIREO PHARMA : Reports Q2 Financial Results and Business Update
2021Albireo Pharma, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 202..
2021Albireo to Present at the 2021 Wedbush PacGrow Virtual Healthcare Conference
2021Albireo to Report Second Quarter 2021 Financial Results on August 5
2021ALBIREO PHARMA : Announces FDA Approval of Bylvay (odevixibat), the First Drug Treatment f..
2021ALBIREO PHARMA : Receives European Marketing Authorization of Bylvay™ (odevixibat), ..
2021ALBIREO PHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
2021MULTIMEDIA UPDATE - Albireo Announces FDA Approval of Bylvay™ (odevixibat), the F..
2021ALBIREO PHARMA : Bylvay Receives FDA Approval as Progressive Familial Intrahepatic Cholest..
2021Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment ..
2021Albireo Pharma, Inc. Announces FDA Approval of Bylvay™, the First Drug Treatment for Pa..
2021ALBIREO PHARMA : Receives European Marketing Authorization of Bylvay (odevixibat), the Fir..
2021ALBIREO PHARMA : Obtains European Marketing Approval for Rare Liver Disease Treatment
2021ALBIREO PHARMA : Receives European Marketing Authorization of Bylvay™ (odevixibat), ..
2021Albireo Pharma, Inc. Announces European Commission Authorization of Bylvay, the First D..
2021Albireo to Present at the William Blair Biotech Focus Conference 2021
2021ALBIREO PHARMA : to Present at Piper Sandler's Virtual EASL Takeaway Day
2021ALBIREO PHARMA : to Present at Piper Sandler's Virtual EASL Takeaway Day
1  2  3  4  5  6Weiter
Anstehende Termine für ALBIREO PHARMA, INC.